104.47 0.00 (0.00%)
After hours: 4:35PM EDT
|Bid||0.00 x 1800|
|Ask||0.00 x 900|
|Day's Range||103.15 - 105.55|
|52 Week Range||99.00 - 130.29|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||67.66|
|Earnings Date||Oct 23, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||120.00|
PALO ALTO, Calif. , Oct. 22, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it has been ranked first in seven categories, including probability of repurchase, overall manufacturer performance, ...
Both Edwards Lifesciences (EW) and Varian Medical (VAR) are brimming with prospects despite the current political disarray within the medical instruments space.
The so-called flash therapy, which is delivered in one to three sessions that each last less than one second, represents a promising new direction in the treatment of cancer.
PALO ALTO, Calif. , Oct. 21, 2018 /PRNewswire/ -- During its Users Meeting at the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting, Varian (NYSE: VAR) shared details of its development ...
PALO ALTO, Calif., Oct. 21, 2018 /PRNewswire/ -- Varian (VAR) today announced the Bravos™ afterloader system for High Dose Rate (HDR) brachytherapy treatments. Based on over five years of in-clinic research, Bravos is an integrated system designed to improve the patient and clinic experience by simplifying brachytherapy treatment and providing greater workflow efficiency. HDR brachytherapy involves delivering radiotherapy by temporarily placing a tiny radioactive source directly into the tumor or other targeted area.
Consortium focused on preclinical research, clinical implementation and advocacy PALO ALTO, Calif. , Oct. 20, 2018 /PRNewswire/ -- To expand the encouraging preclinical and translational research already ...
PALO ALTO, Calif. , Oct. 20, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced its new single-room proton therapy system, ProBeam ® 360°. With a 30 percent smaller footprint than the previous system, ...
Three of the nine analysts covering Varian Medical Systems (VAR) in October have given the stock “strong buy” ratings, three have given it “hold” ratings, and three have given it “sell” ratings.
Varian Medical Systems (VAR) is expected to report net income of $105.05 million in the fourth quarter of fiscal 2018 compared to $82.7 million in the fourth quarter of fiscal 2017, a rise of 27.02%. The company’s net income translates to a net income per share of $1.13 in the fourth quarter of fiscal 2018 compared to $0.89 in the fourth quarter of fiscal 2017. Varian Medical Systems generated free cash flow of $340.0 million in fiscal 2017.
Varian Medical Systems is focused on the design, manufacture, and commercialization of hardware and software products targeted at treating cancer with radiotherapy, stereotactic radiosurgery, brachytherapy, and stereotactic body radiotherapy. Analysts expect Varian Medical Systems’ revenue to rise 3.69% from $739.0 million in the fourth quarter of fiscal 2017 to $766.26 million in the fourth quarter of fiscal 2018. The upcoming quarter could mark the third consecutive quarter of revenue uptick for Varian after four consecutive quarters of revenue falls.
Varian’s gross margins for fiscal 2018 and fiscal 2019 are expected to be 44.23% and 44.15%, respectively. In comparison, the fiscal 2018 gross margins of its peers Globus Medical (GMED), Stryker (SYK), and Zimmer Biomet Holdings (ZBH) are expected to be 77.01%, 66.27%, and 71.91%, respectively. Varian Medical Systems is expected to incur selling, general, and administrative expenses of $140.77 million in the fourth quarter of fiscal 2018 compared to $51.70 million in the fourth quarter of fiscal 2017, a rise of more than 100%.
Varian (VAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Solid prospects in the Oncology segment to boost Varian Medical's (VAR) top-line performance in the fourth quarter of fiscal 2018.
PALO ALTO, Calif. , Oct. 12, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced the acquisition of privately-held software company Noona Healthcare, developer of a cloud-based, mobile service designed ...
PALO ALTO, Calif., Oct. 4, 2018 /PRNewswire/ -- Varian (VAR) today announced it has signed an educational partnership with one of India's leading hospital groups to provide greater access to training in advanced radiotherapy and radiosurgery techniques. The Varian Advanced Clinical School will run courses at the Reliance Group's' Kokilaben Dhirubhai Ambani Hospital (KDAH) in Mumbai, where the region's first Varian Edge™ radiosurgery system was installed in 2016. The clinical school is aimed at radiation oncologists, medical physicists and radiation therapy technologists in India.
PALO ALTO, Calif., Oct. 3, 2018 /PRNewswire/ -- Varian (VAR), today announced it has appointed Kolleen T. Kennedy, formerly president of Varian Oncology Systems (VOS) to a new role as president of Proton Solutions, the division formerly known as Particle Therapy, and chief growth officer. Chris Toth, formerly president of Global Commercial & Field Operations, will succeed Kennedy as the new president of VOS.
PALO ALTO, Calif., Oct. 1, 2018 /PRNewswire/ -- Varian (VAR) today announced a 75-year-old male with lung cancer was the first patient in India to be treated on the Halcyon™ system at Sterling Cancer Hospital in Gujarat. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT), including improved patient comfort and shortening the time from installation to first-treatment without sacrificing quality. The system is well suited to treat cancer patients, offering advanced treatments for lung, prostate, breast, head & neck, and many other forms of cancer.
PALO ALTO, Calif., Sept. 20, 2018 /PRNewswire/ -- The phrase "You have cancer" understandably strikes fear into the hearts of millions of patients diagnosed with the disease every year around the world. Varian (VAR) does not believe it is science fiction and has just published a new vision paper, "The Future of Cancer Care: Moving from Promise to Reality," to describe this future state and detail the challenges that must be overcome to realize it. The Future of Cancer Care shows how advances in diagnostics, genomics, precision medicine, immunotherapy, care coordination, artificial intelligence, data analytics, and access to affordable care all play a part in achieving a world without fear of cancer.
On September 17, Hologic (HOLX) ended the day at $39.53. The stock was down ~0.3% from its previous trading day’s closing price of $39.64. The stock has recuperated some of the losses it saw during the first half of fiscal 2018. It witnessed a declining trend after reporting its 52-week high of $45.09 on January 9, 2018.
PALO ALTO, Calif. , Sept. 12, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced that Jeffrey R. Balser , MD, PhD, president and chief executive officer at Vanderbilt University Medical Center and ...
SAN DIEGO, Sept. 12, 2018 /PRNewswire/ -- Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (VAR). Existing investors, including Altos Capital Partners, Genomic Health, Inc., Domain Associates, VI Ventures, Alexandria Venture Investments, and Sabby Management, also participated in the financing. "We are extremely pleased to have such a strong and diverse syndicate with leaders from the private payer industry, diagnostic strategics, innovators from the technology space, and best-in-class healthcare crossover investors," said Murali Prahalad, Ph.D., president and CEO of Epic Sciences.